Mohammed Said Amer

Mohammed Said Amer

Auto-generated profile, based on publicly available information

Mohammed Said Amer

Department of Small Animal Surgery and Radiology, College of Veterinary Medicine, Cairo University, Giza 12211, Egypt

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Nermeen Adel ElkasabgyNermeen Adel Elkasabgy
Nermeen Adel Elkasabgy
FAFatma S. Abdel-Salam
Fatma S. Abdel-Salam
AMAzza A. Mahmoud
Azza A. Mahmoud
EBEmad B. Basalious
Emad B. Basalious
MAMohammed S. Amer
Mohammed S. Amer
SESeham A. Elkheshen
Seham A. Elkheshen

1 May 2018 in Ceramics International
Verified
Journal Article
Closed access
EKE.M.A. Khalil
E.M.A. Khalil
RYRasha A. Youness
Rasha A. Youness
MAMohammed Said Amer
Mohammed Said Amer
MTMohammed A. Taha
Mohammed A. Taha

24 January 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AEAlaa Eldeeb
Alaa Eldeeb
SSSalwa Salah
Salwa Salah
Mostafa MabroukMostafa Mabrouk
Mostafa Mabrouk
MAMohammed S. Amer
Mohammed S. Amer
Nermeen Adel ElkasabgyNermeen Adel Elkasabgy
Nermeen Adel Elkasabgy
In situ forming implants (IFIs) are non-surgical approach using biodegradable polymers to treat bone fractures. The study aimed at preparing dual-drug-loaded IFIs to deliver pitavastatin (osteogenic drug) and tedizolid (antibiotic) using zein as the implant matrix via solvent-induced phase inversion method. At first, several investigations were done on pitavastatin-loaded zein IFIs, where three concentrations of zein were used (10, 20, and 30% w/v). IFIs were evaluated for their solidification time, rheological properties, injectability, and in vitro release. IFIs containing bioactive glass nanoparticles were prepared by the addition of non-doped bioactive glass nanoparticles (BGT0; 1, 3, 5, and 10% w/v) or titanium-doped bioactive glass nanoparticles (BGT5; 1% w/v) to the selected concentration of zein (30% w/v) and then evaluated. The optimized dual-medicated implant (D-ZIFI 1) containing pitavastatin, tedizolid, sodium hyaluronate (3% w/v), and BGT5 (1% w/v) was prepared and compared to IFI lacking both sodium hyaluronate and BGT5 (D-ZIFI 2). D-ZIFI 1 and 2 sustained the release profiles of both drugs for 28 days. SEM images proved the interconnected porous structure of D-ZIFI 1 due to sodium hyaluronate. In vivo studies on surgically induced bone defects in Sprague–Dawley rats signified the proper accelerated bone healing ability of D-ZIFI 1 over D-ZIFI 2. Results presented D-ZIFI 1 as a promising, effective, non-surgical approach for bone healing.

28 March 2022 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
AEAlaa Eldeeb
Alaa Eldeeb
SSSalwa Salah
Salwa Salah
MAMohammed S. Amer
Mohammed S. Amer
Nermeen Adel ElkasabgyNermeen Adel Elkasabgy
Nermeen Adel Elkasabgy


1 June 2018 in Journal of Musculoskeletal Research
Verified
Journal Article
Closed access
PDF file
DSDina Sabry
Dina Sabry
ASAshraf Shamaa
Ashraf Shamaa
MAMohamed Amer
Mohamed Amer
OEOmar El-Tookhy
Omar El-Tookhy
AAAhmed Abdallah
Ahmed Abdallah
AEAzza Elamir
Azza Elamir